1. Jung KW, Won YJ, Oh CM, Kong HJ, Lee DH, Lee KH, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2014. Cancer Res Treat. 2017; 49:292–305.
2. Min KJ, Lee YJ, Suh M, Yoo CW, Lim MC, Choi J, et al. The Korean guideline for cervical cancer screening. J Gynecol Oncol. 2015; 26:232–239.
3. Huh WK, Ault KA, Chelmow D, Davey DD, Goulart RA, Garcia FA, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Gynecol Oncol. 2015; 136:178–182.
4. Remmerbach TW, Brinckmann UG, Hemprich A, Chekol M, Kühndel K, Liebert UG. PCR detection of human papillomavirus of the mucosa: comparison between MY09/11 and GP5+/6+ primer sets. J Clin Virol. 2004; 30:302–308.
5. Campos NG, Mvundura M, Jeronimo J, Holme F, Vodicka E, Kim JJ. Cost-effectiveness of HPV-based cervical cancer screening in the public health system in Nicaragua. BMJ Open. 2017; 7:e015048.
6. Tantitamit T, Termrungruanglert W, Khemapech N, Havanond P. A model approach for assessing the benefits of HPV testing against cytology in screening for cervical cancer precursors in Thailand. Asian Pac J Cancer Prev. 2017; 18:1271–1275.
7. Armstrong EP. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types. J Manag Care Pharm. 2010; 16:217–230.
8. FUTURE I/II Study Group. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ. 2010; 341:c3493.
9. Cuzick J. Gardasil 9 joins the fight against cervix cancer. Expert Rev Vaccines. 2015; 14:1047–1049.
10. Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015; 372:711–723.
11. Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst. 2010; 102:325–339.
12. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012; 30:Suppl 5. F12–F23.
13. de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017; 141:664–670.
14. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev. 2005; 14:1157–1164.
15. Monsonego J, Zerat L, Syrjänen K, Zerat JC, Smith JS, Halfon P. Prevalence of genotype-specific HPV infection among women in France: implications for screening and vaccination. Gynecol Obstet Fertil. 2013; 41:305–313.
16. Kim MJ, Kim JJ, Kim S. Type-specific prevalence of high-risk human papillomavirus by cervical cytology and age: data from the health check-ups of 7,014 Korean women. Obstet Gynecol Sci. 2013; 56:110–120.
17. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, et al. The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA. 2002; 287:2114–2119.
18. Kwon MJ, Roh KH, Park H, Woo HY. Comparison of the Anyplex II HPV28 assay with the Hybrid Capture 2 assay for the detection of HPV infection. J Clin Virol. 2014; 59:246–249.
19. Hang D, Jia M, Ma H, Zhou J, Feng X, Lyu Z, et al. Independent prognostic role of human papillomavirus genotype in cervical cancer. BMC Infect Dis. 2017; 17:391.
20. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010; 11:1048–1056.
21. Oh JK, Alemany L, Suh JI, Rha SH, Muñoz N, Bosch FX, et al. Type-specific human papillomavirus distribution in invasive cervical cancer in Korea, 1958–2004. Asian Pac J Cancer Prev. 2010; 11:993–1000.
22. So KA, Hong JH, Lee JK. Human papillomavirus prevalence and type distribution among 968 women in South Korea. J Cancer Prev. 2016; 21:104–109.
23. Krashias G, Koptides D, Christodoulou C. HPV prevalence and type distribution in Cypriot women with cervical cytological abnormalities. BMC Infect Dis. 2017; 17:346.
24. Kjær SK, Munk C, Junge J, Iftner T. Carcinogenic HPV prevalence and age-specific type distribution in 40,382 women with normal cervical cytology, ASCUS/LSIL, HSIL, or cervical cancer: what is the potential for prevention? Cancer Causes Control. 2014; 25:179–189.
25. Rhee JE, Shin MY, Kim CM, Kee HY, Chung JK, Min SK, et al. Prevalence of human papillomavirus infection and genotype distribution among high-risk Korean women for prospecting the strategy of vaccine development. Virol J. 2010; 7:201.
26. Bae JH, Lee SJ, Kim CJ, Hur SY, Park YG, Lee WC, et al. Human papillomavirus (HPV) type distribution in Korean women: a meta-analysis. J Microbiol Biotechnol. 2008; 18:788–794.
27. Lee HS, Kim KM, Kim SM, Choi YD, Nam JH, Park CS, et al. Human papillomavirus genotyping using HPV DNA chip analysis in Korean women. Int J Gynecol Cancer. 2007; 17:497–501.
28. Shin HR, Franceschi S, Vaccarella S, Roh JW, Ju YH, Oh JK, et al. Prevalence and determinants of genital infection with papillomavirus, in female and male university students in Busan, South Korea. J Infect Dis. 2004; 190:468–476.
29. Zappacosta R, Lattanzio G, Viola P, Ianieri MM, Gatta DM, Rosini S. A very rare case of HPV-53-related cervical cancer, in a 79-year-old woman with a previous history of negative Pap cytology. Clin Interv Aging. 2014; 9:683–688.
30. Song ES, Lee HJ, Hwang TS. Clinical efficacy of human papillomavirus DNA detection in urine from patients with various cervical lesions. J Korean Med Sci. 2007; 22:99–104.
31. Estrade C, Sahli R, McAdam AJ. Comparison of Seegene Anyplex II HPV28 with the PGMY-CHUV assay for human papillomavirus genotyping. J Clin Microbiol. 2014; 52:607–612.
32. Lillsunde Larsson G, Carlsson J, Karlsson MG, Helenius G. Evaluation of HPV genotyping assays for archival clinical samples. J Mol Diagn. 2015; 17:293–301.